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Abstract 
Background and aim: The prevalence of the hepatitis B virus (HBV) is higher in adults than 
in children. We determined the seroepidemiology of HBV infection in an adult population in 
JiLin, China, to guide effective preventive measures. 
Methods: A cross-sectional serosurvey was conducted throughout JiLin, China. A total of 
3833 people was selected and demographic and behavioral information gathered. Serum 
samples were tested for HBV markers and liver enzymes. 
Results: The prevalence of the hepatitis B surface antigen (HBsAg), the antibody to the 
hepatitis B surface antigen (anti-HBs), the hepatitis B e antigen (HBeAg), the antibody to 
HBeAg (anti-HBe), and the antibody to the hepatitis B core antigen (anti-HBc) were 4.38%, 
35.66%, 1.38%, 6.65%, and 40.88%, respectively. Alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) levels were significantly higher among HBsAg (+) than HBsAg (-) 
subjects. By multivariate logistic regression analysis, independent predictors for chronic HBV 
infection were smoking, poor sleep quality; occupation as private small-businessmen, laborers, 
or peasants; male gender; family history of HBV; personal history of vaccination; and older 
age. Independent predictors for exposure to HBV were large family size, occupation as a 
private small-businessman, male gender, family history of HBV, personal history of vaccina-
tion, and older age. Independent predictors for immunity by vaccination were occupation as a 
private small-businessman, high income, personal history of vaccination, and young age. In-
dependent predictors for immunity by exposure were drinking, male gender, personal history 
of vaccination, and older age. 
Conclusions: The prevalence rate of HBV infection (4.38%) was lower than the previous 
rate of general HBV vaccination. However, 44.59% of the population remained susceptible to 
HBV. The prevalence of HBV infection was high in young adults, private small-businessmen, 
peasants, those with a family history of HBV, and males. Therefore, immunization of the 
non-immune population is reasonable to reduce hepatitis B transmission between adults. 
Key words: hepatitis B; immunity; seroepidemiologic study; vaccine. 
Introduction 
The Hepatitis B virus (HBV) causes liver infec-
tion  that  can  be  life-threatening  and  often  leads  to 
chronic liver disease, liver cirrhosis, and liver cancer. 
HBV infection is a major global health problem [1]. 
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However, to date, relatively little data are available 
concerning  HBV  infection  in  China.  An  epidemic 
survey published in 2006 revealed that 7.18% of Chi-
na’s  population  was  hepatitis  B  surface  antigen 
(HBsAg)- positive. Therefore, China is still considered 
to be a highly endemic region [2-3]. There are about 93 
million HBsAg-positive subjects in China, of whom 
about  20  million  have  chronic  hepatitis  B  infection. 
Around  half-a-million  Chinese  patients  die  from 
hepatitis B-related liver carcinoma and end-stage cir-
rhosis each year [2]. There is no ideal and specific cure 
for HBV infection. The economic burden of HBV in-
fection is substantial because of high morbidity and 
mortality associated with end-stage liver disease, cir-
rhosis, and hepatocellular carcinoma (HCC) [4].  
The modes of transmission of HBV vary between 
different  regional,  gender,  and  age  groups  [4].  The 
sources of infection of hepatitis B are mainly chronic 
hepatitis B patients and asymptomatic viral carriers. 
Infection and viral replication have been confirmed by 
the  presence  of  HBV  DNA  in  body  fluids  [5].  The 
main modes of transmission include mother-to-child 
transmission and blood and body fluids transmission, 
as well as sexual transmission. Perinatal transmission 
is believed to account for 35-50% of carriers although 
horizontal transmission is also important, particularly 
within families [6].  
The national expanded program on immuniza-
tion was instituted in China in 1992. As of December 
2007, 171 counties reported that they had included the 
hepatitis B vaccine into their national infant immun-
ization programs [7]. In China, babies are given the 
hepatitis B vaccine at birth. The national infant im-
munization  program  focuses  on  blocking  moth-
er-to-child transmission of  hepatitis B. The vaccina-
tion program has produced encouraging initial results 
in China. The prevalence of HBsAg was 0.96% and 
2.42% in children aged 1—4 and 5—14, respectively 
[8-10]. In addition to infant immunization, some adult 
members of China's population have been vaccinated 
voluntarily,  outside  national  vaccination  programs. 
However,  older  age  groups,  especially  adults,  have 
not received sufficient attention. Despite the availa-
bility of safe and effective HBV vaccines for over 20 
years, strategies targeting risk groups have failed to 
sufficiently  control  hepatitis  B  transmission  in  the 
current population. HBV transmission has become an 
important mode of infection in adults, mainly because 
of  difficulties  in  risk  identification  and  in  program 
implementation. Therefore, we conducted this study 
to determine the prevalence of HBV infection and the 
major independent risk factors for HBV transmission 
in an adult population in northeast China. 
Materials and Methods 
Design and study population 
A  cross-sectional  seroepidemiologic  study  of 
HBV was carried out in Dehui, Jilin, China in 2007 
(population approximately 410,600). Dehui is located 
81 km from Changchun, the largest city in the area. 
There are 308 villages and 51 neighborhood commit-
tees in Dehui. Earnings of most inhabitants of Dehui 
are in the middle of the income range. The sex and age 
distribution of inhabitants are similar to those of JiLin 
in general. Therefore, Dehui City is representative of 
other areas in the province in terms of the level of 
economic and cultural development.  
A  two-stage,  tiered-system  sampling  method 
was  used.  This  survey  was  comprehensive  and  in-
cluded geographic, economic, cultural, and other pa-
rameters. The first survey covered rural areas while 
the second covered urban areas. Each stage was di-
vided into two layers. In the first layer, the popula-
tions of the villages or neighborhood committees were 
sorted, and the villages or neighborhood committees 
were selected by a computer according to the princi-
ple of equidistant random samples of the population 
size.  We  selected  9  villages  and  11  neighborhood 
committees. In the second layer, the households were 
marked by the distance from the center of the villages 
or neighborhood committees, and they were selected 
according  to  the  principle  of  equidistant  random 
samples  of  the  distance.  Then,  150-200  or  80-100 
households  were  computer-selected  in  villages  or 
neighborhood committees, respectively. A sample of 
the  general  population  in  the  selected  households 
consisting of individuals who were at least 18 years of 
age and had lived in the same area for more than 10 
years was selected using a systematic random 1-in-3 
sampling procedure from the census list, which had 
been updated on February 1, 2007. We defined sample 
sizes of urban and rural groups according to the for-
mula  for the estimation of  sample  size: N =  (t/d)  2 
*(1-p) / p (t=1.96, p=0.09 and d=0.1.5) [11]. The sam-
ples were 1600 and 2400, based on the ratio of urban 
and rural populations of the area, respectively, and 
the total was 4000 (more than the value N). 
In the end, 3833 people agreed to participate in 
the  study,  and  their  serum  samples,  demographic 
information,  and  behavioral  factors  were  collected. 
The response rate was high (95.8%, 3833/4000). When 
we analyzed the relationship between HBV markers 
and liver enzymes, we excluded 75 people who had 
abnormal  autoantibodies,  ceruloplasmin,  and  iron 
tests. They consisted of 30, 29, 16 people, respectively. 
In addition, 98 people were excluded who reported 
consuming at least 40 g of alcohol per day, and 45 Int. J. Med. Sci. 2011, 8 
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hepatitis  C  virus  (HCV)-positive  people  were  ex-
cluded  in  the  analysis  of  the  relationship  between 
HBV markers and liver enzymes. 
Data collection and blood sampling 
The  study  team  consisted  of  physicians  and 
nurses  who were  trained  in  the  survey  methods  in 
order to standardize the data collection, interviews, 
blood drawing, and handling of serum samples. The 
selected participants were asked to fast overnight (≥8 
h)  and  attend  the  local  health  center  during  their 
scheduled  appointment.  The  selected  subjects  were 
visited  at  home  if  they  could  not  attend  the  local 
health center. An interview using a structured ques-
tionnaire  was  conducted  at  the  time  of  the  partici-
pant’s visit. The questionnaire included the following 
questions: (1) Do you sleep well? (2) Do you smoke? 
(3) Have you stopped smoking? (4) How long have 
you  been  smoking?  (5)  Do  you  drink  alcohol  (the 
number and type of drinks per day)? (6) Have you 
donated or received blood? (7) How many people are 
in your family? (8) What is your ethnicity? (9) What is 
your  occupation  (peasant,  laborer,  small  private 
businessman or cadre official)? (10) How many years 
did you study? (11) What is your yearly income? (12) 
Have you been vaccinated for HBV (yes/no)? (13) Do 
you  have  a  family  history  of  HBV?  Information  on 
demographics  and  behavioral  factors  was  obtained. 
The study protocol was approved by the Institutional 
Review Board of the First Hospital of JiLin University. 
After written informed consent was obtained, blood 
samples  were  taken from  each  participant  for  sero-
prevalence analyses. Sera were stored at -200C until 
tested at the First  Hospital of  JiLin University.  An-
thropometric measurements including height, weight, 
and waist and hip circumference were conducted by 
well-trained examiners on individuals wearing light 
clothing.  Waist  circumference  was  measured  to  the 
nearest  0.1  cm  at  the  midpoint  between  the  lower 
borders of the rib cage and the iliac crest. Abdominal 
ultrasonography  was  performed  to  detect  the  pres-
ence  of  fatty  infiltration  in  the  liver  by  physicians 
specializing in diagnostic imaging, all of whom used 
standard criteria in evaluating the images for hepatic 
fat [12]. Fatty liver was diagnosed by concurrence of 3 
ultrasonographers, who were unaware of the subjects’ 
clinical and biochemical status. The results were sup-
plemented  by  the  liver-spleen  density  gradient 
(LSDG) determined with the non-contrast abdominal 
computer tomography (CT) in the local hospital. 
Serological testing 
In  order  to  differentiate  between  the  various 
possible  stages  of  HBV  infection,  a  combination  of 
tests consisting of HBsAg, the antibody to hepatitis B 
surface antigen (anti-HBs), the hepatitis B e antigen 
(HBeAg), the antibody to HBeAg (anti-HBe), and the 
antibody to hepatitis B core antigen (anti-HBc) was 
performed using a commercial ELISA method. HCV 
antibody, ANA, ceruloplasmin, and iron studies were 
assayed by standard methods with kits from Ke Hua 
(Shanghai, China). Persons who tested negative for all 
HBV  markers  were  classified  as  HBV-susceptible. 
Participants  who  were  both  anti-HBc-  and  an-
ti-HBs-positive  were  classified  as  having  been  ex-
posed  to  hepatitis  B  and  possessed  immunity  (im-
munity  by  exposure).  Persons  who  tested  an-
ti-HBc-negative and anti-HBs-positive were classified 
as most probably vaccinated (immunity by vaccina-
tion). Liver enzymes, including alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), and 
-glutamyl transpeptidase-GTP), were evaluated by 
standard methods using kits from Ke Hua (Shanghai, 
China).  Normal  values  were  considered  as:  10–40 
IU/L for AST, and 5–40 IU/L for ALT, and <50 IU/L 
for -GTP. All laboratory analyses were performed at 
the  First  Hospital  of  JiLin  University.  Individuals 
having one or more of the four following criteria were 
defined as having hyperlipidemia: 1) hypertriglycer-
idemia  (>1.7  mmol/L),  2)  HDL-cholesterol  (men, 
<1.04  mmol/L;  women,  <1.3  mmol/  L),  3) 
LDL-cholesterol  (>4.3  mmol/L),  4)  total  cholesterol 
(>6.0 mmol/L). 
Statistical analysis 
Statistical  analyses  were  performed  using  SAS 
software (version 8.0). The overall prevalence of HBV 
markers  among  the  population  in  the  country  was 
calculated  with  95%  confidence  intervals  (CI).  The 
association between the demographic and behavioral 
variables and the biochemical indicators and preva-
lence of hepatitis B markers was evaluated using the 
Chi-square test. Multivariate logistic regression anal-
yses  were  used  to  assess  the  independent  demo-
graphic and behavioral predictors of chronic infection 
(HBsAg  seropositivity),  lifetime  exposure  to  HBV 
infection (anti-HBc seropositivity), immunity by vac-
cination,  and  immunity  by  exposure.  In  the  im-
mune-by-vaccination  group,  9  patients  had  acute 
hepatitis B infection (HBsAg positive) and were ex-
cluded from the analysis. 
The independent variables used were: region of 
residence,  drinking,  smoking,  sleep  quality,  blood 
transfusion,  blood  donation,  family  size,  ethnicity, 
occupation, education level, income, gender, personal 
history of vaccination, family history of HBV, and age. 
The family size in the household was categorized as 
small (less than five persons) vs. large (five or more Int. J. Med. Sci. 2011, 8 
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persons  per  household).  Educational  level  was  de-
fined by the highest educational level achieved and 
was classified based on years of education as group 1 
(<8 years) or group 2 (≥9 years). Drinkers were de-
fined as individuals whose alcohol consumption was 
more than 200 g per week for more than 4 consecutive 
years.  Smokers  were  defined  as  individuals  who 
smoked 10 or more cigarettes a day for more than 4 
consecutive years.  A  two-sided P  <  0.05  result  was 
considered statistically significant. 
Multivariate  logistic  regression  analyses  were 
also used to assess the relationship between the ab-
normal liver enzyme tests with HBsAg (+) vs. HBsAg 
(-), (HBsAg (+) and HBeAg (+)) vs. (HBsAg (+) and 
HBeAg (-)) groups. The other independent variables 
were  region  of  residence,  drinking,  smoking,  sleep 
quality,  blood  transfusion,  blood  donation,  family 
size,  ethnicity,  occupation,  education  level,  income, 
gender, body mass index (BMI), age, fatty liver, and 
hyperlipidemia. A two-sided P < 0.05 result was con-
sidered statistically significant. 
Results 
Demography of the study cohort 
A total of 3833 serum samples was valid and was 
obtained from 1,778 males and 2,055 females in the 
age group 18-79 years with 37.7% (1445/3833) from 
urban and 62.3% (2388/3883) from rural areas. 
Serological markers of hepatitis B immunity 
The results showed that the HBsAg (+) rate was 
4.38%,  95%  CI  3.74  –5.03,  and  1.17%  were  carriers 
[HBsAg (+) and HBcAb (+)]. Anti-HBs was positive in 
35.66% (95% CI, 34.15–37.18%) (n=1367) of the serum 
samples.  Of the 1367 anti-HBs-positive participants, 
471 (12.29%) were anti-HBc-negative, indicating that 
their antibody status was probably due to hepatitis B 
vaccination. Of the serum samples, 44.59% were neg-
ative for any HBV marker. The latter were non-HBV 
immune and needed hepatitis B vaccination; 0.52% of 
the samples were HBsAg, HBeAg, and anti-HBc posi-
tive, indicating active virus replication (Tables 1, 2). 
The seroprevalence of anti-HBc or immunity by ex-
posure increased with age, but the percent of suscep-
tible seroprevalence of HBsAg and immunity by vac-
cination had the opposite trend (Fig. 1, Table 5). 
Univariate, multivariate analysis of serum tests 
(N=3833-218=3615) 
We excluded 218 people who had abnormal au-
toantibodies, ceruloplasmin, or iron tests; those who 
were HCV-positive, or those who reported consum-
ing at least 40 g of alcohol per day. There were 3165 
people in total. Abnormal ALT and AST tests were 
elevated in persons in the HBsAg (+), HBsAg (+), and 
HBeAg  (+)  groups.  However,  the  abnormalities  in 
-GTP levels were not found to be significantly dif-
ferent between HBsAg (+) vs. HBsAg (-) or HBeAg (+) 
vs. HBeAg (-) with HBsAg (+) groups (Table 2). Mul-
tivariate logistic regression analyses were used to as-
sess  the  relationship  among  the  abnormal  liver  en-
zyme tests with HBsAg (+) vs. HBsAg (-) and HBeAg 
(+) vs. HBeAg (-) with HBsAg (+) groups. The results 
were not changed when other risk factors were con-
sidered  (Table  3).  The  rate  of  abnormal  ALT  tests 
(23.81%) was higher than that of abnormal AST tests 
(17.26%) and γ-GT tests (7.7%) in HBsAg (+) subjects, 
especially those who were HBeAg (+). Abnormal ALT 
tests were more frequently abnormal compared with 
other liver enzyme tests in HBV subjects.  
Multivariate logistic regression analysis of HBsAg 
In univariate analysis, HBsAg was significantly 
associated  with  smoking,  sleep  quality,  occupation, 
gender, personal history of vaccination, family history 
of HBV, and age (Table 5). 
On multivariate analysis, seroprevalence of HBV 
remained negatively associated with personal history 
of vaccination and age. People in the 18-29 age group 
had a greater likelihood of having been infected by 
hepatitis B [HBsAg(+)], and a negative trend was seen 
with age. In contrast, a positive association was pre-
sent with smoking, bad sleep quality, being a peasant, 
laborer, or private small-businessman, family history 
of HBV, or male (Table 6, Fig.1). 
Risk factors such as region of residence, blood 
transfusion, blood donation, ethnicity, and education 
level are negative in all the analyses, and Tables 5 and 
6 do not show them. 
Multivariate logistic regression analysis of an-
ti-HBc 
In  univariate  analysis,  anti-HBc  seropositivity 
was significantly associated with smoking, large fam-
ily  size,  family  history  of  HBV,  male  gender,  and 
personal history of vaccination and age (Table 5). 
On  multivariate  analysis,  there  was  a  positive 
association  with  large  family  size,  being  a  private 
small-businessman,  male,  personal  history  of  vac-
cination, family history of HBV, and older age. People 
in the 18-29 age group had a lower likelihood of hav-
ing been exposed to hepatitis B [anti-HBc (+)] and a 
positive trend was seen with age (Table 6). 
Multivariate logistic regression analysis of sero-
logical markers consistent with vaccination 
(immune by vaccination)  
In univariate and multivariate analysis, immun-
ity  by  vaccination  was significantly  associated  with Int. J. Med. Sci. 2011, 8 
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cadre officials, high income, personal history of vac-
cination, and young adults. People in the 18-29 age 
group  had  a  greater  likelihood  of  having  been  im-
munized  by  vaccination  for  hepatitis  B,  compared 
with  those  over  age  70.  They  had  a  64.4%  lower 
chance of having been vaccinated compared with the 
youngest group, and a negative trend was seen with 
age. (Table 6, Fig.1). 
Multivariate logistic regression analysis of sub-
jects with serology consistent with immunity 
post-infection (immune by exposure) 
In univariate and multivariate analysis, immun-
ity  by  vaccination  was significantly  associated  with 
non-drinking, gender, personal history of vaccination, 
and young adult age. People in the 18-29 age group 
had the lowest likelihood of having been exposed to 
hepatitis B, and a positive trend was seen with age 
(Table 6, Fig. 1). 
 
 
 
 
Figure 1. Seroprevalence of HBV markers in Northeast China by age groups 
 
 
 
Table 1. Hepatitis B Markers in the Study Population (n=3833) 
Marker  Number  Percent  95%CI 
HBsAg (+)   168  4.38  3.74-5.03 
Anti-HBs (+)   1367  35.66  34.15-37.18 
HBeAg (+)   53  1.38  1.01-1.75 
Anti-HBe (+)   255  6.65  5.86-7.44 
Anti-HBc (+)  1567  40.88  39.33-42.43 
HBsAg (+) and HBeAg (+)  24  14.29*  8.99-19.58 
 HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis B surface  
antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; anti-HBc, antibody to hepatitis B core antigen; CI: Confidence interval. 
*HBsAg (+) and HBeAg (+) versus HBsAg (+) 
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Table 2. Hepatitis B Marker Combinations in the Study Population (n=3833) 
MODE  Frequency  Percent  Cumulative Frequency   Cumulative Percent 
HBsAg (+)  13  0.34  13  0.34 
HBsAg (+) and  
HBeAg (+) 
1  0.03  14  0.37 
HBsAg (+) and HBeAg (+) and Anti-HBc (+)  20  0.52  34  0.89 
HBsAg (+) and Anti-HBe (+) and Anti-HBc (+)  69  1.80  103  2.69 
HBsAg (+) and  
Anti-HBc (+) 
45  1.17  148  3.86 
Anti-HBs (+)  471  12.29  1169  30.50 
Anti-HBc (+)  499  13.02  698  18.21 
Anti-HBe (+)  35  0.91  3706  96.69 
Anti-HBs (+) and Anti-HBc (+)  782  20.40  3660  95.49 
Anti-HBs (+) and Anti-HBe (+)  11  0.29  3671  95.77 
Anti-HBe (+) and Anti-HBc (+)  51  1.33  199  5.19 
None  1709  44.59  2878  75.08 
Other  127  3.31  3833  100.00 
HBsAg, hepatitis B surface antigen; anti-HBs, antibody to hepatitis B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibody to 
HBeAg; anti-HBc, antibody to hepatitis B core antigen. 
 
 
Table 3. Comparison of Biochemical Data between Different Groups According to HBsAg and HBeAg Status (n=3615) 
  n  Abnormal ALT test,n (%)  Abnormal AST test, n(%)  Abnormalγ-GT test, n(%) 
HBsAg (+) subjects  168  40 (23.81)*  29 (17.26)*  13 (7.7) 
HBsAg (-) subjects  3447  320 (9.28)  183 (5.3)  200 (5.8) 
HBsAg (+)and HBeAg (+)subjects  24  11 (45.83)**  8 (33.33)**  4 (16.7) 
HBsAg (+)and HBeAg (-)subjects  144  29 (20.14)  21 (14.58)  9 (6.3) 
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; -GTP, 
-glutamyl transpeptidase. 
*P <0.001 vs HBsAg (-) subjects, ** P <0.001 vs HBsAg (-)and HBeAg (-) subjects 
 
 
Table 4. Risk for HBsAg and HBeAg Seropositivity Relative to Biochemical Markers among Study Participants 
  OR(95% CI) 
  Abnormal ALT test  Abnormal AST test  Abnormal γ-GT test 
HBsAg (+) subjects  2.66(1.80-3.05)  3.88(2.62-4.15)  1.06(0.52-1.46) 
HBsAg (-) subjects  1(reference)  
HBsAg (+) and HBeAg (+) subjects  3.12(2.12-4.05)  2.81(2.01-3.79)  1.14(0.35-4.50) 
HBsAg (+) and HBeAg (-) subjects 
 
1(reference) 
HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; -GTP, 
-glutamyl transpeptidase;  
Odds ratios with 95% confidence intervals were adjusted for region of residence, drinking, smoking, sleep quality, blood transfusion, blood 
donation, family size, ethnicity, occupation, education level, income, gender, BMI, age, fatty liver, and hyperlipidemia. 
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Table 5. Prevalence of HBV Markers According to Sociodemographic Variables in the Jilin, China (n=3833) 
  Parameters   N  HBsAg, n 
(%) 
Anti-HBc, n 
(%) 
Immune by vaccina-
tion, n (%) 
Immune by exposure, 
n (%)a 
Drinking  No  2532  102 (4.03)  1051 (41.51)  316 (12.37)  603 (23.87) 
  Yes  1301  66 (5.07)  516 (39.66)  155 (12.12)  262 (20.18) 
  P Value    NS  NS  NS  0.0099 
Smoking  No  2449  84 (3.43)  905 (39.4)  317 (12.94)  554 (22.66) 
  Yes  1384  84 (6.07)  602 (43.5)  154 (11.13)  311 (22.55) 
  P Value    0.0001  0.0133  NS  NS 
Sleep quality  Bad  915  57 (6.23)  387 (42.3)  98 (10.71)  192 (21.06) 
  Good  2918  111 (3.8)  1180 (40.44)  373 (12.78)  673 (23.1) 
  P Value    0.0018  NS  NS  NS 
Family size  ≥5 people in house  857  44(5.14)  395(46.09)  110(12.85)  206(24.15) 
  <5 people in house  2976  124(4.17)  1172(39.38)  361(12.13)  659(22.64) 
  P Value    NS  0.0004  NS  NS 
Occupation  Peasant  2277  104(4.57)  924(40.58)  277(12.17)  521(23.93) 
  Laborer  524  26(4.96)  225(42.94)  56(10.69)  116(22.26) 
  Small private busi-
nessmen 
278  22(7.91)  122(43.38)  25(8.99)  63(21.74) 
  Cadre officials  754  16(2.12)  293(39.26)  113(14.99)  165(21.88) 
  P Value    0.0004  0.0001  0.0271  NS 
Income  >800 RMB  949  45(4.74)  400(42.15)  138(14.54)  225(23.81) 
  ≤800 RMB  2884  123(4.26)  1167(40.46)  333(11.55)  640(22.23) 
  P Value    NS  NS  0.0146  NS 
Gender  Female  2055  69(3.36)  775(37.71)  259(12.52)  427(20.82) 
  Male  1778  99(5.57)  792(44.54)  212(12.02)  438(24.7) 
  P Value    0.0006  0.0001  NS  0.0042 
personal history 
of vaccination 
No  2691  146(5.1)  970(34.2)  194(6.8)  306(11.4) 
  yes  974  22(2.2)  597(59.9)  277(27.8)  559(57.4) 
  P Value    0.001  0.001  0.001  0.001 
Family history of 
HBV 
 
Yes   572  106(18.5)  273(47.7)  79(13.8)  119(20.8) 
No   3261  62(1.9)  1294(39.7)  392(12)  746(22.9) 
P Value    0.001  0.001  NS  NS 
Age (years)  18-29  499  32(6.41)  166(33.27)  99(19.84)  97(19.52) 
  30-49   1749  79(4.52)  677(38.71)  184(10.52)  371(21.29) 
  50-69   1478  56(3.78)  658(44.52)  179(12.11)  362(24.51) 
  70 or older   107  1(0.98)  66(61.66)  9(8.4)  35(32.71) 
  P Value    0.0307  0.0001  0.0008  0.0033 
NS: Not significant 
a In the immunity by vaccination model, 9 patients had current infection for hepatitis B (HBsAg positive) and were excluded from the anal-
ysis. 
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Table 6. Multivariate Analyses of Risk Factors for Serological Evidence of Immunity Among Study Participants  
    HBsAg seropositivity  Anti-HBc seropositivity  Immunity by vac-
cination 
Immune by expo-
sure 
  Parameters   Odds ratios with 95% confidence intervals 
Drinking  Yes        0.58*(0.47-0.72) 
  No  1.00 (reference) 
Smoking  Yes  1.61*(1.13-2.29)       
  No  1.00 (reference) 
Sleep equality  Bad  1.79*(1.27-2.524)       
  Good  1.00 (reference) 
Family size  ≥5 people in house    1.35*(1.14-1.60)     
  <5 people in house  1.00 (reference) 
Occupation  Peasant  2.25*(1.12-4.50)  1.11(0.86-1.42)  0.95(0.66-1.369)   
  Laborer  2.26*(1.14-4.48)  1.22(0.95-1.58)  0.73(0.50-1.07)   
  Private 
small-businessman 
3.17*(1.56-6.43)  1.39*(1.03-1.88)  0.55*(0.33-0.89)   
  Cadre officials  1.00 (reference) 
Income  >800 RMB      1.30*(1.20-1.69)   
  ≤800 RMB  1.00 (reference) 
personal 
history of 
vaccination 
No  1.00 (reference) 
  yes  0.49*(0.21-0.58)  3*(2.2-3.4)  6.2*(4.9-6.31)  4.2*(3.5-5.6) 
Family his-
tory of HBV 
 
Yes  2.41*(2.10-2.71)  1.38*(1.16-1.65)     
No   1.00 (reference) 
Gender  Male  1.79*(1.21-2.68)  1.61*(1.36-1.90)    1.64*(1.35-1.99) 
  Female  1.00 (reference) 
Age (years)  18-29  1.00 (reference) 
  30-49   0.65(0.41-1.00)  1.35*(1.09-1.67)  0.46*(0.35-0.61)  1.17(0.91-1.51) 
  50-69   0.488*(0.30-0.78)  1.64*(1.32-2.05)  0.55*(0.41-0.72)  1.39*(1.07-1.80) 
  70 or older   0.15*(0.02-0.85)  3.33*(2.14-5.17)  0.35*(0.17-0.73)  2.02*(1.26-3.23) 
CI: Confidence interval. *P <0.001 vs reference 
Immunity by exposure: anti-HBc (+) and anti-HBs (+); Immunity by vaccination: anti-HBc (-) and anti-HBs (+); 
 
 
Discussion 
Dehui City is representative of JiLin in general 
because  of  most  of  the  inhabitants'  earnings  in  the 
middle of the income range, the sex and age distribu-
tion,  and  the  level  of  economic  and  cultural  devel-
opment in the province. A multistage, tiered-system 
sampling method used to control selection bias pro-
vided a study sample that was a good representative 
of the target population in JiLin. 
HBV  infection  is  considered  a  major  public 
health problem in China [13]. The present study was 
conducted  with  a  systematic  epidemiological  ap-
proach to the current prevalence of HBV infection in 
northeast  China.  At  present,  according  to  our  find-
ings, it seems that 40.88% of the population of north-
east China was anti-HBc (+), implying they had been 
exposed to HBV. Our findings indicate that the sero-
prevalence  of  HBsAg  as  measured  in  the  present 
study  (4.38%)  has  been  reduced  by  more  than 
two-fold in China compared with the rate (9.75%) in 
the pre-vaccination era, and was lower than the rate 
(7.18%) in the National Epidemiological Survey from 
2006 [14]. Northeast China, thus, currently qualifies as 
an intermediate endemic region [3]. The presence of 
HBeAg in serum indicates active viral replication [15]. 
Young  adults  (18-29  years)  have  been  reported  to 
have high rates of HBeAg-positivity (1.62%, 8/499), Int. J. Med. Sci. 2011, 8 
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and the rate of positivity decreased with age due to 
the  spontaneous  seroconversion  to  the  antibody 
against HBeAg. Older carriers have been shown to be 
more likely than younger carriers to clear HBeAg [16].  
Comparisons  between  various  groups  with 
chronic HBV infection showed that the increased liver 
enzyme levels were significantly higher in HBsAg (+) 
people compared with HBsAg (-) people. Moreover, 
people  positive  for  both  HBsAg  and  HBeAg  were 
more likely to have abnormal values of liver enzymes 
compared with HBsAg carriers negative for HBeAg. 
Thus,  measurement  of  aminotransferase  levels  re-
mains the most common and convenient way to iden-
tify liver inflammation in patients with chronic HBV 
infection.  But  the  relationship  may  be  better  estab-
lished by serial observations and analysis rather than 
by  a  single  examination  of  aminotransferase  levels 
[17]. ALT levels have been correlated positively with 
liver  inflammation,  and  patients  with  persistently 
normal ALT levels had significantly lower liver his-
tology scores compared with patients with either per-
sistently or intermittently elevated ALT levels [18-19].  
The higher prevalence of HBV infection among 
males in northeast China is in agreement with recent 
seroprevalence  studies  conducted  in  Hawaii  [20]. 
HBsAg  positivity  rates  were  higher  in  private 
small-businessmen,  peasants  and  laborers,  persons 
with risky social activities or unhygienic living habits, 
and other factors. These factors may increase the risk 
of contact and rate of infection compared with cadre 
officials [20]. These differences were correlated with a 
high  infection  rate,  but  further  investigations  are 
needed for better understanding the mechanisms of 
these relationships. The relationship between age and 
HBsAg  prevalence  that  was  found  in  the  current 
study has also been reported elsewhere, most notably 
by serologic surveys in Korea [21]. Significantly lower 
risk for HBsAg positivity in older persons might have 
resulted from a spontaneous clearance of HBsAg over 
time (a 40% cumulative rate of HBsAg seroclearance 
has been observed among HBV carriers after 25 years) 
[22].  In  addition,  mortality  due  to  HBV-related  se-
quelae may lead to decreased prevalence in older age 
(probability of survival is 84% at 5 years and 68% at 10 
years for HBsAg (+) patients with compensated cir-
rhosis) [20]. 
Regarding  family  size  and  family  history  of 
HBV, HBV is more frequently transmitted in the fam-
ilies with hepatitis B patients [23]. The difference in 
sex  ratio  in  persons  aged  18-29  years  versus  70  or 
older, age 30-49, or age 50-69 was statistically signifi-
cant.  There  were  more  males  in  the  younger  than 
older  age  groups  (data  not  shown).  The  factors  of 
male gender, personal history of vaccination, and be-
ing  a  private  small-businessman  had  interactive  ef-
fects with age in HBV infection and exposure to HBV. 
There may have been a confounding effect in the in-
dependent  risk  factors  which  were  synergistic.  The 
reason for the sex difference is unclear. It could have 
been due to differences in the immune response to the 
HBV  infection  [24].  Infection  at  birth,  risky  sexual 
behavior, or drug use were the main reasons identi-
fied for HBV infection of young people in other parts 
of the world [25]. These data may also explain why 
the risk in older persons was lower than that in the 
younger group [24].  
The prevalence of HBV infection was found not 
to be different between rural and urban areas (data 
not shown). On the other hand, living in a rural area 
was  not  found  as  a  risk  factor  for  transmission  of 
hepatitis B. Some studies have reported that there was 
a  significant  seropositivity  difference  between  rural 
and urban regions [20, 26]. There are 56 ethnic groups 
in China and the lifestyle of the minority ethnic pop-
ulation is considerably different from the Han major-
ity  ethnic  population.  Ethnic  differences  and  HBV 
infection have not been well described in northeast 
China.  We  investigated  possible  differences  among 
ethnic groups, but found no association between HBV 
contact, infection, and ethnicity. However long-term 
poor  quality  of  sleep  may  inhibit  the  immune  re-
sponse, resulting in poor defense, and HBV infection 
[27]. 
In the current study, 44.59% were negative for all 
hepatitis B markers. This high proportion of the pop-
ulation is disturbing, but not very surprising because 
the impact of the national infant immunization pro-
gram  would  not  have  been  seen  in  the  age  groups 
studied.  The  large  number  of  residual  susceptible 
individuals  found  in  this  study  reflects  the  inade-
quacy  of  voluntary  adult  vaccination  that  occurred 
outside the national vaccination campaign. Hepatitis 
B  vaccine  failure  has  been  reported  to  occur  in 
5%–10%  of  individuals  completing  a  full  course  of 
three doses [28], but this would explain less than half 
of the seronegative results.  
Adult vaccination has already had a substantial 
effect on the general level of hepatitis B immunity in 
China. In this cohort of people from JiLin province, 
almost 35.66 % (1367/3833) were immune, and 12.28% 
of this immunity was attributable to vaccination ra-
ther than natural infection. The immunity rate from 
past infection is higher than the 5% rate reported in 
blood  donors  in  1987—before  vaccination  became 
widespread [29]. 
The substantial impact of adult vaccination was 
greatest  among  people  who  were  aged  18-29,  had 
high income, were cadre officials, had a personal his-Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
330 
tory of vaccination, and were not concentrated in the 
demographic or lifestyle risk groups for whom vac-
cination is officially recommended. This represents an 
ongoing  public  health  challenge.  At  the  same  time, 
primary  hepatitis  B  vaccine  failure  and  rapidly  de-
clining anti-HBs titres after vaccination may also af-
fect the effectiveness of the immunity program [28]. 
People in the youngest age group had a greater like-
lihood  of  being  currently  immune  by  vaccination 
against hepatitis B, compared with those aged over 70 
having significantly (64.4%) less chance of being im-
mune  by  vaccination.  But  males  in  the  older  age 
group likely became immune by exposure. The reason 
may be related to immune maturation and opportu-
nities  for  exposure  to  HBV  to  generate  antibodies, 
resulting in seroconversion [23]. Booster doses of the 
hepatitis B vaccine are regarded as unnecessary on the 
premise that a rapid anamnestic response will occur 
on challenge [30], and this policy is supported by the 
demonstration  of  antibody  production  after  booster 
doses of the vaccine and the lack of reports of acute 
icteric hepatitis among ―high risk‖ vaccinees [31-32]. 
Personal  history  of  vaccination  was  determined  by 
patient recall which affects the accuracy and impact of 
the study. We do not know vaccination age, Hep B 
genotype,  vaccination  doses,  number  of  inoculated, 
and  duration  of  HBV  infection.  However  personal 
history of vaccination was associated with decreasing 
HBsAg-positivity  and  increasing  HBsAb  positivity. 
The positive results increase our confidence in the use 
of the vaccine [8]. 
The  multivariate  logistic  regression  analysis 
showed that independent predictors for chronic HBV 
infection and exposure to HBV were family history of 
HBV, and large family size. This does not identify a 
mode of transmission, but suggests that vertical and 
sexual transmission may be involved as they are well 
known risk factors. Further studies will be required to 
determine the actual modes of transmission. 
Therefore, vaccination program for all newborns 
should be continued. Susceptible adults whose HBV 
markers  are  all  negative  should  have  repeat  or 
catch-up immunization, especially those individuals 
who have risk factors of having poor sleep quality, 
being  private  small-businessmen,  having  a  family 
history  of HBV,  having no  personal history of vac-
cination, and being a young male adult. HBV carriers 
need to be closely monitored or treated. The findings 
of the current study add to the knowledge of hepatitis 
B  epidemiology  in  areas  with  sizable  high-risk 
groups,  demonstrating  the  importance  of  screening 
programs  for  hepatitis  B.  Mass  screening  permits 
baseline estimates of prevalence and provides insight 
into appropriate vaccination strategies. Furthermore, 
because  of  China’s  high  incidence  of  hepatitis 
B-related  hepatocellular  carcinoma,  screening  pro-
grams are clinically significant for facilitating referral 
of newly diagnosed cases to appropriate medical care 
[31, 33]. 
Conclusions 
Strong  associations  between  HBV  infection  or 
immunity  were  observed  regarding  the  gender,  oc-
cupation, personal history of vaccination, and age in 
adults. There has been a decrease in the prevalence of 
HBV infection since the National Expanded Program 
on  Immunization.  Mother-to-fetal  vertical  transmis-
sion of HBV is well controlled. Transmission between 
adults has become the most common mode of HBV 
spread.  While  the  survey  focused  on  a  region  in 
northeast China, it is likely that similar results may be 
found elsewhere in the country. Identifying groups at 
risk for susceptibility can assist in the development of 
national  strategies  to  target  specific  groups  for 
cost-effective salvage vaccination programs for adults 
in the future.  
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